NCT07559526Completed
Nutritional Assessment of Patients With Non-small Cell Lung Cancer Treated With Osimertinib
Source: ClinicalTrials.gov · Last updated 30 Apr 2026
Brief summary (registry, in English)
Nutritional assessment of patients with non-small cell lung cancer treated with osimertinib. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and is a leading cause of morbidity and mortality worldwide. Between 35% and 65% of NSCLC patients experience nutritional problems or malnutrition, which significantly affects their prognosis and quality of life. This study aims to describe the nutritional status and body composition of NSCLC patients treated with osimertinib, an oral tyrosine kinase inhibitor, while also assessing the prevalence of sarcopenia, presarcopenia, and dynapenia. Additionally, we explore the relationship between dose-limiting toxicities (DLTs) and nutritional status, as well as the impact of nutritional status on quality of life using the EQ-5D scale.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 25 (actual)
- First submitted
- 24 Apr 2026
- Start date
- 20 Mar 2024
- Primary completion date
- 24 May 2024
- Lead sponsor
- Fundacin Biomedica Galicia Sur
- Diseases
- Lung cancer
- NCT number
- NCT07559526
What you commit to
- Study type: Observational
- Participants enrolled: 25
- From 20 Mar 2024 to the primary completion date, 24 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients currently receiving osimertinib treatment for an indication other than those authorized in the product information (compassionate use).
Other
- Patients who have discontinued osimertinib treatment.
- Patients who do not sign the informed consent form.
- Withdrawal criteria:
- \- Revocation of consent to participate in the study by the patient.
Who the study is looking for
- Patients over 18 years of age.
- Patients diagnosed with NSCLC.
- Patients undergoing osimertinib treatment who collect their medication at the Pharmacy Outpatient Clinic of the Álvaro Cunqueiro Hospital.
- Patients who have consented to participate by signing the informed consent form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Complex of Vigo Coordinator of this site? Confirm its status | Vigo | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.